Spatial behaviour of Tursiops truncatus along the Ligurian sea cost: preliminary results
... et Gnone et al., (2006), cette espèce est décrite essentiellement comme côtière fréquentant surtout les faibles profondeurs moins que -100m. À l'opposé de ces auteurs, Gannier (2005) confirmait la distribution bimodale de cette espèce et affirmait avoir observé les grands dauphins à l'aplomb du talus continental sur une profondeur de 350m en Méditerranée Nord Occidentale. ...
Inventory of dolphins in the eastern region of Tunisia (Teboulba): Little effort has been made to monitor populations of delphinids along the east coasts of Tunisia, considered to be a very productive coastal ecosystem conducive to the establishment of cetaceans. This work is a first contribution to the study of the dolphinids in this. The main results show that the prospected area shelters two species of delphinidae occupying two different ecotypes. 91 groups of Tursiops truncatus, 9 groups of Stenella coeruleolba and 3 mixed groups of Stenella and Tursiops were observed. The group size of Tursiops was smaller than those of Stenella. The group size of these two species varies with depth, distance from the coast and the occurrence of immatures. The two species occupy the study area differently, where Tursiops spend more time on feeding and depredation activities. On the other hand, Stenella takes advantage of the study area to socialize, travel and feeding. All these results allow us to assume that the eastern zone of Tunisia can be considered as areao of interest and even an important marine mamals area dor these two dolphins.
... INTRODUCTION -Bottlenose dolphins presence along East Ligurian coastal waters is widely documented (1) . Establishing bottlenose dolphin long-term patterns of occurrence is fundamental to better understand relationships between dolphins and their habitat, including human activities such as fishing and vessels traffic. ...
Bottlenose dolphins presence along East Ligurian coastal waters is widely documented. Establishing bottlenose dolphin long-term patterns of occurrence is fundamental to better understand relationships between dolphins and their habitat, including human activities such as fishing and vessels traffic. Here we describe the experimental use of an Ecological Acoustic Recorders (EAR) to monitor the presence of bottlenose dolphins in front of Tino Island, Gulf of La Spezia, Easter Ligurian Sea. The EAR is a bottom-moored recorder with a bandwidth of 25 kHz, which allows the detection of both dolphin whistles and echolocation clicks. One EAR was deployed approximately half a mile off Tino Island at a depth of 24.9 meters. The EAR has been recording 30 seconds of the acoustic environment every 5 minutes from the 15th of July to the 2nd of September 2009 and more than 14.000 acoustic files were stored. The results reveal a different use of the habitat, when comparing day and night hours, with a peak of dolphins presence during the night. This pattern has never been described before in this area and could be due to interactions between bottlenose dolphins and human activities, including vessel traffic and fishing. These preliminary results demonstrate the efficiency of passive acoustic methods for monitoring cetacean populations and their habitat over extended periods, producing new data in relation to their presence along the coast.
... Moreover the presence of cameras and hydrophones will allow to monitor the presence of cetaceans. In coastal regions, bottlenose dolphins long-term patterns of occurrence are fundamental to better understand relationships between dolphins and their habitat, including human activities such as fishing and vessel traffic [21]. The presence of this new observation point will surely enlarge the knowledge on the relationship amongst coastal (about 600 m of depth) and offshore (about 2000 m of depth in DYFAMED site) processes in the Ligurian Sea. ...
The overall objective of this proposal is to build an advanced and original prototype specifically devoted to seafloor and water-column monitoring as starting Italian contribution to the further development of the EMSO Ligurian Sea node. In detail the aim of the observatory is to ensure real-time continuous acquisition of geophysical, oceanographic and biological data by a cable system from a marine depth of about 500 m to the shore station.
... Bottlenose dolphins occur in most coastal waters of the basin and have been reliably reported in the waters of Albania, Algeria, Croatia, Cyprus, France, Gibraltar, Greece, Israel, Italy, Montenegro, Morocco, Slovenia, Spain, Tunisia and Turkey. The presence of the bottlenose dolphin in the Pelagos Sanctuary has been reported along the west coast of France (Ripoll et al., 2001;Gannier, 2005), east coast of Liguria (Gnone et al., 2006), north Tuscany , Tuscany Archipelago (Rosso et al., 2006;Nuti et al., 2007), west and south coast of Corsica (Dhermain, 2004;Dhermain and Cesarini, 2007), and the north coast of Sardinia (Lauriano, 1997;Fozzi et al., 2001). Occasional sightings have also been reported in the west coast of Liguria (Azzellino et al., 2008;Bearzi et al., 2008). ...
The sera of 180 human samples were tested for the presence of antibodies against Borrelia burgdorferi using the ELISA
(enzyme-linked immunosorbent assay) technique. Out of 180 sero-samples, 46 (25.55%) were positive. Females of the age range
18-35 years had the highest rate of sero-positive samples 14 (38.88%), while the highest percentage of sero-negative samples was
found in males of the age range 50-80 years. The other sero-positive samples were: 6 (26.08%), 6 (25%) and 3 (11.53%) in males of
ages between 18-35, 35-50 and 50-80 years, respectively, and 11 (29.72%) and 6 (17.64%) in females in the age ranges 35-50 and
50-80 years, respectively. The mean concentration of Anti- B. burgdorferi antibody was higher (16.7 U/mL) when compared with
mean concentration of normal value (5.5 U/mL), P < 0.001.
EGFr (Epidermal growth factor receptor) overexpression has been detected in many tumors of epithelial origin, specifically in breast cancer and it is often associated with tumor growth advantages and poor prognosis. The nimotuzumab is a genetically engineered humanized MAb (monoclonal antibody) that recognizes an epitope located in the extracellular domain of human EGFr. The aim of this study was to assess the pharmacokinetics of nimotuzumab in patients with locally advanced breast cancer who are receiving neoadyuvant therapy combined with the AC chemotherapy regimen (i.e., 60 mg/m2 of Doxorubicin and 600 mg/m2 of Cyclophosphamide in 4 cycles every 21 days). A single center, non-controlled, open Phase I clinical trial, with histopathological diagnosis of locally advanced stage III breast cancer, was conducted in 12 female patients. Three patients were enrolled at each of the following fixed dose levels: 50, 100, 200 and 400 mg/week. Multiple intermittent short-term intravenous infusions of nimotuzumab were administered weekly, except on weeks 1 and 10, when blood samples were drawn for pharmacokinetic assessments. Nimotuzumab showed dose-dependent kinetics. No anti-idiotypic response against nimotuzumab was detected in blood samples of participants. There was not interaction between the administration of nimotuzumab and chemotherapy at the dose levels studied. The optimal biological doses ranging were estimated to be 200 mg/weekly to 400 mg/weekly.
EGFr (Epidermal growth factor receptor) overexpression has been detected in many tumors of epithelial origin,
specifically in breast cancer and it is often associated with tumor growth advantages and poor prognosis. The nimotuzumab is a
genetically engineered humanized MAb (monoclonal antibody) that recognizes an epitope located in the extracellular domain of
human EGFr. The aim of this study was to assess the pharmacokinetics of nimotuzumab in patients with locally advanced breast
cancer who are receiving neoadyuvant therapy combined with the AC chemotherapy regimen (i.e., 60 mg/m2 of Doxorubicin and 600
mg/m2 of Cyclophosphamide in 4 cycles every 21 days). A single center, non-controlled, open Phase I clinical trial, with
histopathological diagnosis of locally advanced stage III breast cancer, was conducted in 12 female patients. Three patients were
enrolled at each of the following fixed dose levels: 50, 100, 200 and 400 mg/week. Multiple intermittent short-term intravenous
infusions of nimotuzumab were administered weekly, except on weeks 1 and 10, when blood samples were drawn for
pharmacokinetic assessments. Nimotuzumab showed dose-dependent kinetics. No anti-idiotypic response against nimotuzumab was
detected in blood samples of participants. There was not interaction between the administration of nimotuzumab and chemotherapy at
the dose levels studied. The optimal biological doses ranging were estimated to be 200 mg/weekly to 400 mg/weekly.
to December 2006, with statistical data for the calendar year 2005.
ResearchGate has not been able to resolve any references for this publication.